Last quarter (Q2 2023), Horizon Therapeutics's total revenue was $944.96M, an increase of 7.82% from the same quarter last year. In Q2, Horizon Therapeutics's net income was $127.07M. See Horizon Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 3.64B	$ 3.63B	$ 3.23B	$ 2.20B	$ 1.30B	$ 1.21B
Cost of Revenue	$ 903.44M	$ -920.20M	$ -794.51M	$ 532.70M	$ 362.18M	$ 391.30M
Gross Profit	$ 2.74B	$ 2.71B	$ 2.43B	$ 1.67B	$ 937.85M	$ 816.27M
Operating Expense	$ 2.23B	$ -2.09B	$ -1.89B	$ 1.18B	$ 800.28M	$ 775.25M
Operating Income	$ 511.33M	$ 673.54M	$ 553.49M	$ 485.14M	$ 137.57M	$ 41.02M
Net Non Operating Interest Income Expense	$ -68.68M	$ -83.71M	$ -81.06M	$ -59.62M	$ -87.09M	$ -121.69M
Other Income Expense	$ -7.73M	$ 5.57M	$ -3.79M	$ -23.88M	$ -70.71M	$ -2.46M
Pretax Income	$ 443.83M	$ 526.94M	$ 462.83M	$ 401.64M	$ -20.22M	$ -83.13M
Tax Provision	$ 5.90M	$ 5.45M	$ -71.66M	$ 11.85M	$ -593.24M	$ -44.75M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 437.93M	$ 521.44M	$ 534.48M	$ 389.80M	$ 573.02M	$ -38.38M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 3.13B	$ -3.01B	$ -2.68B	$ 1.72B	$ 1.16B	$ 1.17B
Net Income From Continuing And Discontinued Operation	$ 437.93M	$ 521.44M	$ 534.48M	$ 389.80M	$ 573.02M	$ -38.38M
Normalized Income	$ 241.15M	-	-	$ 416.26M	$ 623.95M	$ -35.97M
Interest Expense	$ 22.48M	-	-	$ 59.62M	$ 87.09M	$ 121.69M
EBIT	$ 419.72M	$ 526.94M	$ 462.83M	$ 461.26M	$ 66.86M	$ 38.56M
EBITDA	$ 605.02M	$ 925.24M	$ 821.77M	$ 740.71M	$ 304.02M	$ 288.32M

Currency in USD

Horizon Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing